With $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a one-two punch to combat BRAF-mutated colorectal cancer and its “dismal prognosis.”

CHICAGO, December 13, 2023 (Newswire.com) - Many cancers caused by the mutation of the BRAF gene respond well to a class of immunotherapies known as BRAF-inhibitors. BRAF-mutated colorectal cancer, however, almost never does. Doctors have known this for years, but they are yet to find a treatment that works well for most patients.

“BRAF-inhibitors provide very different clinical outcomes,” said Dr. Scott Kopetz, a Professor and Associate Vice President for Translational Integration at The University of Texas MD Anderson Cancer Center. “They work amazingly well in melanoma, for example, but are less effective in colorectal cancer.”

“BRAF [in colorectal cancer] is that odd uncle who doesn’t behave like the rest of the family. The black sheep. Is he even related? The usual rules don’t apply.”

Dr. Kopetz and his team’s most recent studies of this black sheep are now moving from research in mice to clinical trials in humans. These trials were approved by the National Cancer Institute in October and will launch in early 2024. 

The GI Research Foundation helped support the work with mice models, along with several other aspects of the team’s BRAF-related research. The $3.5 million grant is part of the foundation’s massive CA CURE initiative.

“Last year, we were able to deliver more than $18 million to researchers across the country to improve diagnostics and develop immunotherapies and personalized vaccines in gastrointestinal cancers through CA CURE,” said Katie Chudnovsky, chair of the GI Research Foundation’s Board of Directors. “Patients need treatments like those being developed by Dr. Kopetz – so very urgently – and we are thrilled to see this team’s work moving to clinical trials so quickly.”

BRAF-mutated colorectal cancer comes with a “dismal prognosis,” according to research in the International Journal of Molecular Sciences, and the median patient survives less than a year.

This new form of treatment for BRAF-mutated colorectal cancer relies on what Kopetz called a “two-hit hypothesis.” That is, these cancers are caused by the combination of mutations in the BRAF gene and epigenetic dysregulation. Epigenetic dysregulation refers to the fact that behaviors and environment can impact how a person’s genes behave.

Here, researchers have found that a mutation to the BRAF gene changes the production of proteins that cause healthy cells to grow into cancerous tumors. Other forms of BRAF-mutated cancer respond well to BRAF-inhibitor immunotherapy that can halt the production of those proteins. 

In BRAF-mutated colorectal cancer, however, another piece of DNA is unable to express itself entirely. Those genes typically create natural tumor suppressors that fight early cancer growth. Carbon molecules called methyl groups attach themselves to the DNA and prevent the DNA from building cancer-suppressing proteins. That “methylation” is the epigenetic dysregulation in this case, likely caused by inflammation, diet, or external environmental factors.

If doctors can stop the proteins that cause cancer and stop the bromodomains, they might be able to produce a one-two punch to combat their double hit hypothesis. The treatment would slow BRAF-mutated colorectal cancer growth and encourage natural cancer suppressors.

That idea will be tested in the human trials that were recently approved by the National Cancer Institute. A BRAF-inhibitor, an EGFR-inhibitor, and a bromodomain-inhibitor will be administered to patients. This combined treatment was developed by Kopetz and his colleague Dr. Kunal Rai, an Associate Professor of Genomic Medicine at MD Anderson.

The research moved from the GI Research Foundation-funded mouse models to human trials exceptionally quickly, according to Kopetz.

“It’s rare for the pieces to come together like this,” he said. “Lots of times, this would be two years of work to get the human trials up and running. But we were able to show how clearly this approach worked in multiple mouse models and that really sped things up.”

Other funding from the GI Research Foundation will help speed things up even further. “The new technologies and techniques that Dr. Kopetz and his team are exploring will give them the ability to innovate that much faster. It provides the entire community with the means to gather high-quality data more quickly and get it into trials and ultimately into the clinic,” said Dr. David Rubin. Rubin is the Joseph B. Kirsner Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition at University of Chicago Medicine. He is also GI Research Foundation’s Senior Scientific Advisor. 

“The GI Research Foundation has a legacy of funding high risk-high reward and innovative science, and doing so efficiently and extraordinarily effectively. Kopetz and his colleagues were recipients of a dedicated campaign that we launched in 2022 to tackle the most difficult challenges of colorectal cancer.”

“Support from the GI Research Foundation allows us to accelerate our work and try some out of the box stuff,” Kopetz said. “We have amazing animal models, but there’s no substitute for understanding cancer and treatments with the patients themselves. We want to develop the tools we need so we can learn as much as possible from them and help them as much and as quickly as we can.”

About the GI Research Foundation

The GI Research Foundation was founded in 1961 by grateful patients and friends of the late Dr. Joseph B. Kirsner, a pioneer in gastroenterology who devoted his life to medicine, teaching, and patient care. Today, the University of Chicago Medicine’s Digestive Diseases Center, which is supported by the foundation, is internationally recognized for research-driven medicine and its team of highly specialized physicians. For more information, see: https://giresearchfoundation.org/

About the University of Chicago Digestive Diseases Center

The Digestive Diseases Center at the University of Chicago Medicine is a collaborative, multidisciplinary network of physicians, researchers and affiliated health professionals who share a legacy of innovation and a common purpose: to improve the lives of patients who suffer from digestive diseases. For more information, see: https://www.uchicagomedicine.org/conditions-services/digestive-diseases

Contact Information:
Jackie Casey
Executive Director
[email protected]
312-332-1350


Original Source: Research for the Treatment of a 'Black Sheep' Cancer Moves to Human Clinical Trials

SPARKS, Md., December 12, 2023 (Newswire.com) - TridentCare is pleased to announce the addition of Chris Tomlinson, MBA, CRA, FAHRA to the organization and its executive team. Chris recently assumed the role of Senior Vice President, Laboratory Operations and oversees the entire TridentCare Laboratory Network. His focus is on enhancing workflows, unifying TridentCare’s national lab network and growing both the primary customer segments (skilled nursing facilities) and commercial, governmental, and home-based lab programs. Chris says, “I am thrilled to join a company with the foresight to meet their customers ‘where they are’. This direction is where healthcare is evolving and as a lab and imaging leader, I can think of no better role for my background. I am excited to partner with a great group of leaders and further develop the next generation of healthcare services."

Chris has an extensive background in Radiology/Imaging & Clinical Lab/Pathology Services with over 20+ years of professional success. CEO Dan Buning indicates, "As a member of the Executive Leadership Team (ELT), Chris’s background in Radiology/Imaging is an added bonus; he will be able to lend his nationally recognized imaging expertise to TridentCare’s national portable imaging business where needed. Offering reliable, accurate, and timely lab service to both our core and new customer segments is a critical part of our company’s future.” 

Prior to joining TridentCare, Chris was the Enterprise Vice President at Jefferson Health in Philadelphia where he oversaw the Clinical Lab/Pathology and Radiology/Imaging Services lines for eighteen (18) hospitals and clinics and became the first enterprise leader for the health system. As the Enterprise Vice President, Chris’s mandate was to organize, group, and consolidate service lines, standardizing lab and imaging across the different hospitals and partnership models. A huge undertaking with over 11M lab tests and more than 2M imaging studies per year.

Before his time with Jefferson Health, Chris spent fifteen (15) years at Children’s Hospital of Philadelphia where he led the radiology/imaging enterprise and launched a number of imaging joint ventures with other hospitals. Prior to that, Chris spent time at Arthur Andersen’s Business Consulting division where he focused on healthcare, and other offerings.

“Chris brings an enormous amount of insight and operational lab expertise that we know will complement and enhance our current infrastructure and national footprint,” says TridentCare COO Jeff Hooper. “Chris will help us accelerate our growth into non-traditional market segments for laboratory where we believe we are in a position to be one of the only national players in portable laboratory services.”

About TridentCare 

Based in Sparks, Maryland, TridentCare is the leading provider of portable diagnostic services in the Country, operating in 38 states, servicing a wide variety of patients and clients. Each day, the company deploys experienced medical professionals and leading-edge technology to provide imaging, phlebotomy, laboratory, oxygen, and vascular services to tens of thousands of patients nationwide. For more information about TridentCare, please visit TridentCare.com, and follow us on LinkedIn, Facebook and Instagram.

Contact Information:
Deborah Shelton
[email protected]


Original Source: TridentCare to Grow and Enhance Its Laboratory Services Business With the Addition of a Seasoned Diagnostic Operator

Preventogen’s FDA-Cleared Microbicidal Liquid Polymer Ensures the Eradication of These Dangerous Pathogens on Contact While Forming a More Effective and Measurable Barrier to Optimize Healing

ST. LOUIS, December 12, 2023 (Newswire.com) - Many may not know the immense problem of antimicrobial resistance. A routine surgery or common cut can quickly become life-threatening due to an infection; an otherwise healthy person can quickly become fatally ill. These superbugs have already affected millions of Americans, and the problem of antimicrobial resistance is accelerating in our post-COVID world. 

SEEKING A SOLUTION

In 2019, the Centers for Disease Control (CDC) in Atlanta published a 180-page compendium of the deadliest antibiotic-resistant threats: “Antibiotic resistance threats in the United States, 2019”. This groundbreaking work highlighted the 18 most dangerous pathogens and classified them as Urgent, Serious, or Concerning threats.

In its most recent publication, “COVID-19 Reverses Progress in Fight Against Antimicrobial Resistance in the U.S.”, the CDC cited a rise of 15% in hospitalization-related infections from 2019 to 2020. These pathogens are becoming stronger and more resistant on a global scale. In a January 2022 report, antimicrobial resistance was shown to be a leading cause of death globally, with the most significant burden in low-resource countries.

A SOLUTION WITH ROBUST KILLING PROPERTIES

Prevent-Plus has a solution in Preventogen™, a non-antibiotic approach to infection prevention. Since its inception in 2016, Prevent-Plus has performed in-vitro and flesh pad laboratory testing. After reading the 2019 CDC report, those most dangerous pathogens became vital targets. 

Preventogen’s effectiveness has been definitively shown against every pathogen it has been tested against.  All testing has been completed at Nelson Labs^®, a Sotera Health company and an industry-leading, global provider of laboratory testing, performing over 900 rigorous microbiological and analytical laboratory tests.

“Our company is dedicated to the prevention of infection, which is why we continue to collect evidence to demonstrate Preventogen’s safety and efficacy in both lab and clinical settings,” said Brad Chartrand, CEO of Prevent-Plus. 

Prevention is an FDA-cleared topical liquid polymer that kills bacteria, viruses, and fungi on contact. When applied to the skin, the patented polymer dries quickly. It creates a non-antibiotic, elastomeric barrier designed to protect wounds against water, germs, and dirt, providing clinicians with a more effective tool to fight against surgical-site infections and chronic wounds. Importantly, because the polymer is not a drug, there are no known organisms with tolerance or resistance to Preventogen. 

CLINICAL PROOF OF SUCCESS

Preventogen’s safety and efficacy were demonstrated in a randomized, prospective trial in deformity correction with external fixators, one of the most infection-prone procedures in medicine, with the Preventogen patients showing 0 infections and the control arm with a 23% infection rate. 

“With the use of Preventogen, we are seeing a dramatic decrease in bacterial colonization. We use this product as part of our infection prevention protocol in lower-extremity salvage and reconstruction in high-energy trauma and are also tracking its efficacy vs. superbugs. So far, we are very impressed,” commented Dr. Edgardo Rodriguez-Collazo, Director of the Postdoctoral Fellowship Complex Deformity Correction and Microsurgical Limb Reconstruction at Ascension Health.

“Preventogen lays down an impermeable barrier to bacteria, preventing biofilm formation. In our early clinical cases, we have found that chronic wounds thought not to be healable now go on to heal. We see demand for this product growing exponentially as the number of patients with chronic wounds grows annually; clinicians and payors are always looking for ways to heal more wounds in less time,” said Dr. Mary E. Hanley DO, FUHM, CWSP, FAPWCA, Medical Director Roper St. Francis Healthcare Wound Care, Hyperbaric Medicine and Limb Preservation Program.

About Preventogen™

Preventogen is a non-antibiotic, FDA-cleared microbicidal liquid agent that actively kills viruses, fungi, and bacteria on contact by lysing the cell membrane, leading to quick cell death. The liquid quickly dries, creating a transparent, biodegradable, odorless, and elastomeric film barrier. The flexible film barrier protects the wound from water, dirt, and oxygen. Carbon dioxide infused into Preventogen during manufacturing is released and lowers the wound bed's pH, which helps promote healing. 

We are exploring additional strategic partnerships and market expansion based on robust scientific and clinical data.

About Prevent-Plus

Prevent-Plus, LLC provides innovative infection prevention polymer science used by professional healthcare providers and patients for wound care, infection prevention, and optimized healing across a wide range of clinical applications and specialties.

Contact Information:
Brad Chartrand
CEO, Prevent-Plus
[email protected]
(518) 796-8786

Lena Geandreau
Creative Director
[email protected]
(917) 848-0138
Related Images


Original Source: Preventogen is a New Tool in the Fight Against Antibiotic-Resistant Infections Caused by Superbugs, a Leading Cause of Death Worldwide

Arrow Benefits Group Celebrates Community Accolade Encouraging Diversity

PETALUMA, Calif., December 12, 2023 (Newswire.com) - Arrow Benefits Group Senior Benefits Advisor Rosario Avila has been honored with the North Bay Business Journal’s Diversity in Business Award. Avila is recognized as an outstanding diverse leader, working to empower the community in the North Bay. The award celebrates individuals whose contributions build community and a positive work environment where all people are represented and supported. 

Avila has been involved in several local organizations such as Sonoma Family Meal, Hispanic Chamber of Commerce, LatinX Hub, and Los Cien. In her role as the leader of Arrow’s Spanish Language Division — Alianza — Avila brings her passion for community to the workplace. “I’m very humbled by this award,” says Avila. “As the youngest child of immigrants, I saw firsthand how thoughtful communication among different people helps to limit misunderstandings. I’m so proud that Arrow understands this and works to ensure our clients receive culturally sensitive information.” To learn about Avila and Arrow’s diversity work, please visit https://www.arrowbenefitsgroup.com/spanish-language-division/ or call 707-799-9274.

Translating for a population and its language is more than just converting information; it takes a deeper understanding, re-interpretation, and communication of words and ideas. Avila understands this concept exceptionally well. She helped Arrow build its Spanish Division, Alianza, to do exactly that, allowing an entire diverse community to make the best use of its benefits and reduce financial losses for its clients — the program had been a win-win for employees and employers alike. 

Avila’s efforts to ensure equitable access to information have been recognized in the past. She has been nationally recognized as an Employee Benefits Advisor of the Year and received an Excellence in Advising Award. Avila was honored with the North Bay Business Journal Latino Business Leadership award in 2018. 

“One of Arrow’s goals is to build a diverse, equitable, and inclusive environment where our employees can grow, thrive, and be supported,” says Joe Genovese, Arrow’s CEO and Managing Principal. “This award is a great achievement for Rosario and the Arrow team at large.”

About Arrow Benefits

For more than 30 years, Arrow has been a true partner to employers by delivering employee benefits expertise, service excellence, and strategic consulting designed to meet the unique needs of its clients. In 2019, Arrow Benefits Group co-founded Patriot Growth Insurance Services (PGIS), which is now one of the largest benefits consulting and brokerage networks in the country. Patriot and Arrow are aligned with TRUE Network of Advisors, a national collaboration of independent agencies and brokerages. Learn more at https://www.arrowbenefitsgroup.com/ or call 707-992-3780.

Be Social with Us: https://www.linkedin.com/company/arrow-benefits-insurance-services/ 

Contact Information:
Jenny Kaplan
JKPR
[email protected]
415-342-2209


Original Source: Local Benefits Advisor Honored With Prestigious Diversity in Business Award

Exclusive partnership provides a complete, end-to-end value-based care delivery, payment model and advanced analytics solution for payers, providers, payviders and large employers to improve quality, cost control, health equity, patient/member satisfaction, and more

RICHARDSON, Texas, December 12, 2023 (Newswire.com) - MedeAnalytics, a healthcare analytics software-as-a-service (SaaS) leader enabling clinical, financial and operational analytics for healthcare providers, payers, payviders, employers, and other key stakeholders in the ecosystem, announced today an exclusive strategic partnership with HSBlox, a leading technology platform for value-based care contract management and administration that operationalizes complex contracts, enables transparency, and simplifies communication between stakeholders. This partnership combines best-in-class, outcomes-based analytics with contract and financial administration into one powerful platform, providing an end-to-end value-based care solution purpose-built to meet all needs of healthcare organizations in successfully moving to more value-based care programs and whole-person healthcare. When coupled with the MedeAnalytics Managed Action^TM ecosystem and strategic consulting services, the combined platforms and partnership will represent the industry’s most complete value-based care management solution.

The Health Care Payment & Learning Action Network survey of health plan executives showed two-sided risk contracts expanded 24.5% over the previous year. Transitioning from fee-for-service to Alternative Payment Models (APMs), especially risk-based APMs, is a daunting challenge for both providers and payers as it can be difficult to operationalize and scale across multiple contracts and payment models. Data sharing continues to be a pain point. Being able to share timely data with proactive and actionable insights is an imperative for accountable care with failure often leading to fines, penalties, and an inability to achieve reimbursement targets.

"As healthcare organizations expand the number of value-based care contracts and alternative payment models they support, they need a scalable solution that’s low-lift and provides actionable insights," said Rahul Sharma, CEO of HSBlox. "That's why this partnership is powerful. The MedeAnalytics customer base represents the broadest reach of value-based care stakeholders in the industry supporting providers, managed care organizations, commercial payers and brokers, and this combined solution will provide a level of support unmatched in the industry. The scalability and flexibility of our platform combined with MedeAnalytics can support all the nuanced needs associated with successful programs."

By seamlessly integrating into the MedeAnalytics end-to-end platform, providers, health plans and employers can engage in a single solution and extend into payment modeling and facilitation. This means customers will be uniquely enabled to surface insights, prioritize action, and measure impact in the most efficient environment available in the industry. As one example, organizations can leverage historical utilization patterns and performance to identify and model different types of value-based care programs and payment models. With this increased visibility and data integration, MedeAnalytics can deliver insights and recommendations that are suitable for a particular program, model out the contract terms, and operationalize that contract to improve the quality of care and performance while keeping costs down and complying with regulations.

"Value-based care represents a better future for healthcare, but without smart solutions using cutting-edge innovation like our data fabric, augmented analytics, and best-in-industry data interoperability, organizations will continue to struggle with the multiple, often disconnected platforms and blending, prepping and normalizing data between systems," said Steve Grieco, CEO of MedeAnalytics. "By integrating the HSBlox platform into our ecosystem, organizations will not only gain complete visibility into their APM performance, but also, they will have our industry-leading Managed Action ecosystem infrastructure to ensure all activities supporting value-based care transformation are coordinated and aligned with the most important outcomes. This advancement will maximize value-based care performance and provide better patient outcomes at a lower cost of care delivery."

If you’d like to learn more about this exclusive partnership and how it can propel and scale healthcare organizations into value-based care, please reach out. We also offer strategic consulting services through MedeConsulting. Schedule a complimentary discovery call with our experts to uncover potential impact. 

###

About HSBlox

HSBlox empowers healthcare organizations with the tools and support to manage value-based programs successfully and sustainably. Our platform provides end-to-end administration, simplifies communication between stakeholders, and operationalizes complex contracts for the full range of reimbursement models. Wherever you are on your value-based journey, we’ll meet you there with smart, secure, scalable solutions. To learn more, browse our website and visit our LinkedIn page.

About MedeAnalytics^®
With over 30 years in the industry, MedeAnalytics is a leader in healthcare analytics. Using a data fabric-enabled cloud platform, our SaaS solutions run on cutting-edge innovation and enable measurable impact for healthcare payers, providers and payviders. With the most advanced data orchestration and interoperability in healthcare, organizations count on us to deliver actionable insights that improve financial, operational and clinical outcomes. To date, we’ve helped uncover millions of dollars in savings annually. To learn more, browse our website, LinkedIn and featured insights.

Media Contacts:

HSBlox
Philip Anast
Amendola Communications
312.576.6990
[email protected]

MedeAnalytics
Caryn Tomer
AVP, Marketing for MedeAnalytics
618.579.9717
[email protected]

Contact Information:
Caryn Tomer
AVP, Marketing
[email protected]
6185799717


Original Source: MedeAnalytics and HSBlox Partner to Provide the First End-to-End Platform to Power Value-Based Care Success via a Single Solution

OnPage Announces Enhanced Integration With Slack to Empower Healthcare Teams With Unparalleled Critical Alerting and 'Paging' Capabilities Directly From Slack

WALTHAM, Mass., December 12, 2023 (Newswire.com) - OnPage, a leading provider of a HIPAA-compliant secure messaging platform, is proud to announce the launch of its new integration with Slack, marking a monumental breakthrough in healthcare communication technology. This groundbreaking integration with Slack is set to redefine the landscape of critical messaging within healthcare organizations.

With healthcare's increasing need for secure and efficient HIPAA-compliant communication, the integration between OnPage and Slack emerges as a game-changer. This integration isn't just an upgrade; it's a transformative shift that ensures every critical moment in healthcare is addressed with precision and immediacy.

Slack, a widely recognized collaboration and intelligent productivity platform known for its robust security features, enables customers to configure their Slack instance to meet their HIPAA compliance needs. For Enterprise Grid customers, Slack offers encryption at rest and in transit, two-factor authentication, session management, and mobile device management, making it a trusted choice among healthcare providers.

Slack’s collaboration and productivity capabilities, coupled with OnPage’s critical messaging, accountability, real-time responsiveness, on-call scheduling, and escalation capabilities, will provide healthcare teams with a single, dedicated space for urgent alerts and eliminate the risk of crucial information getting lost in day-to-day communication.

Accommodating schedules, shifts, and escalation policies in critical events is paramount in healthcare. OnPage's robust scheduling capabilities seamlessly integrate with professionals' shifts, ensuring that critical messages reach the right individual at the right time on their OnPage phone application. Additionally, customizable escalation policies within OnPage guarantee that if an urgent message remains unacknowledged for a specified period, it automatically escalates to the next responsible personnel, ensuring no critical matter goes unattended.

The integration is undergoing a pilot phase at a major healthcare organization, enhancing communication among healthcare providers, dispatchers, and EMT staff without disrupting workflow.

Key features include seamless critical message exchange, leveraging OnPage's scheduler and escalation capabilities, acknowledging and responding to critical messages within Slack, and access to a comprehensive message audit trail.

"We are thrilled to introduce this groundbreaking integration between OnPage and Slack. This collaboration empowers healthcare professionals with a solution that bridges communication gaps, ensures real-time responsiveness, and revolutionizes critical messaging within healthcare organizations," said Judit Sharon, CEO of OnPage. 

The integration enables swift care team mobilization, facilitating timely alerts to providers and fostering a culture of accountability. Comprehensive visibility empowers senders to track message delivery and intervene promptly if needed.

The OnPage and Slack integration is poised to reshape critical messaging in healthcare, bringing unparalleled efficiency, fostering accountability, and ensuring real-time responsiveness — an advancement in how healthcare professionals engage and respond to urgent moments.

About OnPage

OnPage is an Incident Alert Management platform that elevates critical notifications to the right person on call to remediate critical events. With Alert-Until-Read capabilities, dynamic digital schedules, escalation criteria and redundancies, OnPage ensures that critical alerts are never missed. Learn more.

Contact Information:
Ritika Bramhe
Head of Marketing
[email protected]
(781) 916-0040


Original Source: Revolutionizing Healthcare Communication: OnPage Unveils Innovative Slack Integration

Easy access to language interpretation for hospitals, health care systems, and providers that use Epic medical software.

HOUSTON, December 11, 2023 (Newswire.com) - MasterWord Services, Inc. announces the integration and availability of interpreting services through Epic system, enabling access to the same live, remote language interpreters already supporting thousands of healthcare providers and patients nationwide. This integration marks a significant stride in enhancing communication in healthcare, ensuring convenient availability of essential language support for effective patient care.

The integration with Epic software offers hospital administrators an efficient and streamlined approach to language services. Healthcare providers gain instant access to professional interpreters in hundreds of languages directly within the Epic system, enhancing patient satisfaction and quality of care. This integration is a testament to MasterWord's commitment to connecting people across language and culture, reflecting the same innovative spirit and vision that has been the company's cornerstone for over 30 years.

MasterWord's integration streamlines workflows, allowing clinicians to focus on patient care rather than administrative tasks. The system maintains adherence to healthcare regulations, including those specified in Section 1557 of Patient Protection and Affordable Care Act. It achieves this by automatically recording every language service interaction in the patient's electronic health record, ensuring a thorough and precise documentation of care.

Ludmila Golovine, President and CEO of MasterWord, states, "Our integration with Epic is a game-changer in the realm of healthcare communication. We are honored to offer a solution that not only streamlines the process for medical professionals but also significantly enhances the quality of care for patients facing language barriers,” adding, “This step is in line with our commitment to safeguard equitable access to healthcare for all, especially as we see a nationwide increase in the need for rare and indigenous language support."

MasterWord's integration with Epic is now available to hospitals and healthcare systems seeking to improve their language services. 

About MasterWord

MasterWord, ranked in the top eight interpreting providers globally by CSA Research, enhances patient-centered care by delivering exceptional language access across 350+ languages, including American Sign Language and rare and indigenous languages. A trauma-informed organization with three decades of experience, MasterWord partners with health care systems, hospitals, and providers for sensitive, confidential, and time-critical language services, compliant with HIPAA, ACA Section 1557, ADA, CLAS, and Title VI. For more information, please visit: www.masterword.com.

Contact Information:
Ryan Foley
Director of Communications
[email protected]
346-744-7158


Original Source: MasterWord Makes Connecting With Healthcare Interpreters Easy With Epic Integration